- Trials with a EudraCT protocol (116)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
116 result(s) found for: Fine Needle Aspiration.
Displaying page 1 of 6.
EudraCT Number: 2005-000403-33 | Sponsor Protocol Number: GEICAM/2004-04 | Start Date*: 2005-06-01 |
Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM) | ||
Full Title: Randomized clinical trial to evaluate the predictive accuracy of a gene expression profile-based test to select patients for preoperative taxane/anthracycline chemotherapy for stage I-III breast ca... | ||
Medical condition: Patients with histologically confirmed stage I-III invasive carcinoma of the breast for whom adjuvant chemotherapy is indicated. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005715-22 | Sponsor Protocol Number: D6990C00001 | Start Date*: 2006-02-21 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone ma... | ||
Medical condition: postmenopausal women with hormone receptor positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Prematurely Ended) NO (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000676-42 | Sponsor Protocol Number: PAP_RI1_2019/1 | Start Date*: 2023-01-24 |
Sponsor Name:University Center Hospital of Guadeloupe | ||
Full Title: Efficacy of metformin versus sitagliptin on benign thyroid nodules size in type 2 diabetes: a 2-years prospective multicentric study | ||
Medical condition: newly diagnosed subjects with uncomplicated T2DM and begnin TN of at least 2 cm of size, after pregnancy exclusion if women | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002662-38 | Sponsor Protocol Number: ZD1839IL/0704 | Start Date*: 2004-11-12 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARC... | ||
Medical condition: squamous cell carcinoma of the head and neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) LT (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010288-17 | Sponsor Protocol Number: 1516 | Start Date*: 2009-07-13 |
Sponsor Name:Karolinska Hospital | ||
Full Title: Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS) | ||
Medical condition: Polycystic ovary syndrome (PCOS) is the most common hormonal aberration in women of fertile age, with a prevalence of 5-10%, and is associated with chronic anovulation, hyperandrogenism and PCO mo... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005135-26 | Sponsor Protocol Number: PM0259 CA304 J1 | Start Date*: 2005-05-02 |
Sponsor Name:Pierre Fabre Médicament | ||
Full Title: ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN ... | ||
Medical condition: Stage III Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-002991-15 | Sponsor Protocol Number: SOLTI-1804 | Start Date*: 2019-11-04 |
Sponsor Name:SOLTI | ||
Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 | ||
Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001904-10 | Sponsor Protocol Number: PM0259CA301J1 | Start Date*: 2004-09-15 |
Sponsor Name:Pierre Fabre Médicament represented by IRPF | ||
Full Title: Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic ... | ||
Medical condition: Treatment in locally advanced or metastatic non-small-lung cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) EE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-000358-21 | Sponsor Protocol Number: D7919C00706 (ZD1839IL/0706) | Start Date*: 2004-10-06 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiother... | ||
Medical condition: Untreated, unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004126-10 | Sponsor Protocol Number: GO27983 | Start Date*: 2012-04-19 | |||||||||||
Sponsor Name:Genentech Inc. | |||||||||||||
Full Title: A PHASE Ib/II STUDY OF GDC-0068 OR GDC-0980 WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTH... | |||||||||||||
Medical condition: Castration-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GR (Completed) CZ (Completed) ES (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002764-79 | Sponsor Protocol Number: RESCUE | Start Date*: 2023-04-13 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
Full Title: Diagnostic yield of Endoscopic aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr-) vs endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis ... | |||||||||||||
Medical condition: Intraductal papillary mucinous intraductal neoplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005653-22 | Sponsor Protocol Number: NL13PAR | Start Date*: 2014-08-25 |
Sponsor Name:Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital [...] | ||
Full Title: TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. | ||
Medical condition: The surgical procedure of parotidectomy whereby a protid tumor is removed. During this procedure the wound surface will be covered by the surgical sealing patch TachoSil instead of the use of a c... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003188-24 | Sponsor Protocol Number: CA184-587 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases | |||||||||||||
Medical condition: Metastatic uveal melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000693-30 | Sponsor Protocol Number: 56UCS2017 | Start Date*: 2019-11-25 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. | |||||||||||||
Medical condition: Women with confirmed high grade serous or endometrial epithelial ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000810-12 | Sponsor Protocol Number: CO41101 | Start Date*: 2019-12-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META... | ||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer (TNBC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Ongoing) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002721-30 | Sponsor Protocol Number: NIPU | Start Date*: 2021-01-14 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) | |||||||||||||
Medical condition: Malignant pleural mesothelioma (MPM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004792-36 | Sponsor Protocol Number: CA209-017 | Start Date*: 2012-09-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Revised Protocol N... | |||||||||||||
Medical condition: Squamous cell Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) ES (Ongoing) AT (Completed) HU (Completed) CZ (Completed) NO (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005019-15 | Sponsor Protocol Number: CCTL019C2202 | Start Date*: 2018-11-08 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N... | |||||||||||||
Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001750-42 | Sponsor Protocol Number: CA209-214 | Start Date*: 2014-11-11 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma | |||||||||||||||||||||||
Medical condition: Advanced or metastatic renal cell carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) SE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) CZ (Ongoing) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000727-25 | Sponsor Protocol Number: 47582 | Start Date*: 2017-03-28 |
Sponsor Name:Isala Klinieken | ||
Full Title: The effect of ARTISS on latissimus dorsi donor site seroma formation after breast reconstruction: a randomised controlled trial. | ||
Medical condition: The aim of this study is to investigate the effect of the fibrin sealant ARTISS compared with our standard care on total volume of donor site seroma after harvesting a LD in immediate breast recons... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.